Table 2.

Primary Outcomes in Various Follow-Up Periods

OutcomeNumber of Event (%)Adjusted Hazard Ratio and 95% CI
SIM vs ATOREZ-SIM vs ATORSIM vs EZ-SIM
SIM (n = 337)EZ-SIM (n = 564)ATOR (n = 1510)HR (95% CI)PHR (95% CI)PHR (95% CI)P
3-month follow-up
    IS15 (4.5)16 (2.8)43 (2.8)1.35 (0.73–2.49).3320.84 (0.46–1.55).5761.61 (0.77–3.36).204
    Death from any cause9 (2.7)7 (1.2)14 (0.9)3.14 (1.28–7.74).0131.99 (0.76–5.22).1621.58 (0.56–4.49).391
    MI0 (0.0)3 (0.5)0 (0.0)NANANANANANA
    Composite endpointa25 (7.4)25 (4.4)60 (4.0)1.62 (1.01–2.63).0511.05 (0.65–1.72).8361.54 (0.87–2.74).139
1-year follow-up
    IS42 (12.5)42 (7.4)92 (6.1)1.91 (1.31–2.79).0011.16 (0.80–1.70).4391.64 (1.06–2.56).028
    Death from any cause26 (7.7)20 (3.5)75 (5.0)1.56 (0.98–2.48).0600.88 (0.53–1.46).6161.78 (0.98–3.24).060
    MI3 (0.9)6 (1.1)8 (0.5)1.47 (0.36–5.93).5932.10 (0.66–6.71).2110.70 (0.16–3.02).630
    Composite endpointa67 (19.9)64 (11.3)173 (11.5)1.64 (1.23–2.20).0011.04 (0.77–1.40).8081.59 (1.11–2.26).011
Overall follow-up
    IS57 (16.9)52 (9.2)114 (7.5)2.03 (1.46–2.82)<.0011.20 (0.85–1.69).2961.69 (1.14–2.50).008
    Death from any cause41 (12.2)35 (6.2)124 (8.2)1.26 (0.87–1.81).2250.81 (0.55–1.20).2971.54 (0.97–2.46).067
    MI7 (2.1)6 (1.1)16 (1.1)1.71 (0.68–4.31).2590.96 (0.36–2.58).9421.77 (0.58–5.44).320
    Composite endpointa95 (28.2)87 (15.4)243 (16.1)1.55 (1.22–1.99)<.0011.00 (0.77–1.28).9781.56 (1.16–2.11).004
OutcomeNumber of Event (%)Adjusted Hazard Ratio and 95% CI
SIM vs ATOREZ-SIM vs ATORSIM vs EZ-SIM
SIM (n = 337)EZ-SIM (n = 564)ATOR (n = 1510)HR (95% CI)PHR (95% CI)PHR (95% CI)P
3-month follow-up
    IS15 (4.5)16 (2.8)43 (2.8)1.35 (0.73–2.49).3320.84 (0.46–1.55).5761.61 (0.77–3.36).204
    Death from any cause9 (2.7)7 (1.2)14 (0.9)3.14 (1.28–7.74).0131.99 (0.76–5.22).1621.58 (0.56–4.49).391
    MI0 (0.0)3 (0.5)0 (0.0)NANANANANANA
    Composite endpointa25 (7.4)25 (4.4)60 (4.0)1.62 (1.01–2.63).0511.05 (0.65–1.72).8361.54 (0.87–2.74).139
1-year follow-up
    IS42 (12.5)42 (7.4)92 (6.1)1.91 (1.31–2.79).0011.16 (0.80–1.70).4391.64 (1.06–2.56).028
    Death from any cause26 (7.7)20 (3.5)75 (5.0)1.56 (0.98–2.48).0600.88 (0.53–1.46).6161.78 (0.98–3.24).060
    MI3 (0.9)6 (1.1)8 (0.5)1.47 (0.36–5.93).5932.10 (0.66–6.71).2110.70 (0.16–3.02).630
    Composite endpointa67 (19.9)64 (11.3)173 (11.5)1.64 (1.23–2.20).0011.04 (0.77–1.40).8081.59 (1.11–2.26).011
Overall follow-up
    IS57 (16.9)52 (9.2)114 (7.5)2.03 (1.46–2.82)<.0011.20 (0.85–1.69).2961.69 (1.14–2.50).008
    Death from any cause41 (12.2)35 (6.2)124 (8.2)1.26 (0.87–1.81).2250.81 (0.55–1.20).2971.54 (0.97–2.46).067
    MI7 (2.1)6 (1.1)16 (1.1)1.71 (0.68–4.31).2590.96 (0.36–2.58).9421.77 (0.58–5.44).320
    Composite endpointa95 (28.2)87 (15.4)243 (16.1)1.55 (1.22–1.99)<.0011.00 (0.77–1.28).9781.56 (1.16–2.11).004

The HRs were adjusted for all covariates listed in Table 1 and Supplemental Table 2. NA, not applicable.

a

Any one of IS, HS, cardiovascular death, or MI.

Table 2.

Primary Outcomes in Various Follow-Up Periods

OutcomeNumber of Event (%)Adjusted Hazard Ratio and 95% CI
SIM vs ATOREZ-SIM vs ATORSIM vs EZ-SIM
SIM (n = 337)EZ-SIM (n = 564)ATOR (n = 1510)HR (95% CI)PHR (95% CI)PHR (95% CI)P
3-month follow-up
    IS15 (4.5)16 (2.8)43 (2.8)1.35 (0.73–2.49).3320.84 (0.46–1.55).5761.61 (0.77–3.36).204
    Death from any cause9 (2.7)7 (1.2)14 (0.9)3.14 (1.28–7.74).0131.99 (0.76–5.22).1621.58 (0.56–4.49).391
    MI0 (0.0)3 (0.5)0 (0.0)NANANANANANA
    Composite endpointa25 (7.4)25 (4.4)60 (4.0)1.62 (1.01–2.63).0511.05 (0.65–1.72).8361.54 (0.87–2.74).139
1-year follow-up
    IS42 (12.5)42 (7.4)92 (6.1)1.91 (1.31–2.79).0011.16 (0.80–1.70).4391.64 (1.06–2.56).028
    Death from any cause26 (7.7)20 (3.5)75 (5.0)1.56 (0.98–2.48).0600.88 (0.53–1.46).6161.78 (0.98–3.24).060
    MI3 (0.9)6 (1.1)8 (0.5)1.47 (0.36–5.93).5932.10 (0.66–6.71).2110.70 (0.16–3.02).630
    Composite endpointa67 (19.9)64 (11.3)173 (11.5)1.64 (1.23–2.20).0011.04 (0.77–1.40).8081.59 (1.11–2.26).011
Overall follow-up
    IS57 (16.9)52 (9.2)114 (7.5)2.03 (1.46–2.82)<.0011.20 (0.85–1.69).2961.69 (1.14–2.50).008
    Death from any cause41 (12.2)35 (6.2)124 (8.2)1.26 (0.87–1.81).2250.81 (0.55–1.20).2971.54 (0.97–2.46).067
    MI7 (2.1)6 (1.1)16 (1.1)1.71 (0.68–4.31).2590.96 (0.36–2.58).9421.77 (0.58–5.44).320
    Composite endpointa95 (28.2)87 (15.4)243 (16.1)1.55 (1.22–1.99)<.0011.00 (0.77–1.28).9781.56 (1.16–2.11).004
OutcomeNumber of Event (%)Adjusted Hazard Ratio and 95% CI
SIM vs ATOREZ-SIM vs ATORSIM vs EZ-SIM
SIM (n = 337)EZ-SIM (n = 564)ATOR (n = 1510)HR (95% CI)PHR (95% CI)PHR (95% CI)P
3-month follow-up
    IS15 (4.5)16 (2.8)43 (2.8)1.35 (0.73–2.49).3320.84 (0.46–1.55).5761.61 (0.77–3.36).204
    Death from any cause9 (2.7)7 (1.2)14 (0.9)3.14 (1.28–7.74).0131.99 (0.76–5.22).1621.58 (0.56–4.49).391
    MI0 (0.0)3 (0.5)0 (0.0)NANANANANANA
    Composite endpointa25 (7.4)25 (4.4)60 (4.0)1.62 (1.01–2.63).0511.05 (0.65–1.72).8361.54 (0.87–2.74).139
1-year follow-up
    IS42 (12.5)42 (7.4)92 (6.1)1.91 (1.31–2.79).0011.16 (0.80–1.70).4391.64 (1.06–2.56).028
    Death from any cause26 (7.7)20 (3.5)75 (5.0)1.56 (0.98–2.48).0600.88 (0.53–1.46).6161.78 (0.98–3.24).060
    MI3 (0.9)6 (1.1)8 (0.5)1.47 (0.36–5.93).5932.10 (0.66–6.71).2110.70 (0.16–3.02).630
    Composite endpointa67 (19.9)64 (11.3)173 (11.5)1.64 (1.23–2.20).0011.04 (0.77–1.40).8081.59 (1.11–2.26).011
Overall follow-up
    IS57 (16.9)52 (9.2)114 (7.5)2.03 (1.46–2.82)<.0011.20 (0.85–1.69).2961.69 (1.14–2.50).008
    Death from any cause41 (12.2)35 (6.2)124 (8.2)1.26 (0.87–1.81).2250.81 (0.55–1.20).2971.54 (0.97–2.46).067
    MI7 (2.1)6 (1.1)16 (1.1)1.71 (0.68–4.31).2590.96 (0.36–2.58).9421.77 (0.58–5.44).320
    Composite endpointa95 (28.2)87 (15.4)243 (16.1)1.55 (1.22–1.99)<.0011.00 (0.77–1.28).9781.56 (1.16–2.11).004

The HRs were adjusted for all covariates listed in Table 1 and Supplemental Table 2. NA, not applicable.

a

Any one of IS, HS, cardiovascular death, or MI.

Close
This Feature Is Available To Subscribers Only

Sign In or Create an Account

Close

This PDF is available to Subscribers Only

View Article Abstract & Purchase Options

For full access to this pdf, sign in to an existing account, or purchase an annual subscription.

Close